AGT Spins Out Addimmune, Focusing on Functional HIV Cure

Original Post on Genengnews By: Alex Philippidis According to CEO Jeff Galvin, the cell and gene therapy developer hopes its Addimmune spinout will pick up where AGT leaves off in developing a one-time treatment for HIV, in light of positive early data.   A leading developer of gene and cell therapies is spinning out a…

Read More

American Gene Technologies Spinoff Sets Sights on Advancing Cell Therapy for HIV

Original Post on Precision Medicine Online By: Jessica Kim Cohen   NEW YORK – American Gene Technologies (AGT), a 15-year-old privately held biotech firm, is spinning off its HIV drug development program into a separate company that will exclusively focus on advancing therapeutics against the AIDS-causing virus. The new company, Addimmune, will separate from AGT within a year…

Read More

POZ Magazine: HIV Advocates Inspire in “The Cure Chronicles”

POZ Magazine profiles AGT's video series The Cure Chronicles

Original post on By Trent Straube Sexual molestation as a child, an abusive father, the foster care system, violent street gangs, an HIV diagnosis as a teenager. “Anything you can think of that’s bad, I’ve been through it,” says Latina HIV advocate Maria Mejia in an episode of The Cure Chronicles. Despite her challenges, Mejia’s story is one of…

Read More

ShareTreck: Raj Natarajan Interviews American Gene™ CEO, Jeff Galvin

ShareTreck Interviews Jeff Galvin on the Future of Medicine

Raj Natarajan, host of ShareTreck, goes behind the scenes with Jeff Galvin, Founder and CEO of American Gene™ in this compelling interview to learn how gene therapy works, and what it means for people with deadly diseases, as well as how it will impact the current pharmaceutical landscape. The company is currently in the midst…

Read More

From Lab to Launch Podcast: Testing a Gene Therapy to Potentially Cure HIV & Fundamentally Change Healthcare with Jeff Galvin

CEO Jeff Galvin was interviewed on the From Lab to Launch podcast

Have a listen. From Lab to Launch by Qualio Jeff is the CEO and founder of American Gene Technologies®. He earned his BA degree in Economics from Harvard and has more than 30 years of business and entrepreneurial experience including founder or executive positions at various Silicon Valley startups. Following his startup experience, he…

Read More

Unboxing Biotech Analyst Report: The Foundation Behind a Potential HIV Cure

Unboxing Biotech Analyst Report examines AGT103-T

Download the Report The exact origins of Human Immunodeficiency Virus (HIV) are not precisely known, but researchers theorize that the virus may have originated in chimpanzees,1and then crossed to humans via blood borne pathway. It is not radically different from many of the other retroviruses that exist in nature such as the avian sarcoma virus…

Read More

CityBiz: American Gene Technologies® Appoints Dr. Jeff Boyle as Chief Science Officer

As seen in CityBiz, Jeff Boyle, PhD was appointed as chief science officer

Original post on American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the company’s FDA-approved HIV gene therapy clinical trial that expects to see first indications of efficacy in Q3, as well as continue…

Read More